Navigation Links
GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
Date:12/8/2010

COCOA, Fla., Dec. 8, 2010 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced commencement of the Phase 2 clinical trial for its stand-alone gas cylinder NITROSYL System. The initial indication to be studied for nitric oxide delivered via the GeNO NITROSYL System is as a diagnostic agent for administration as an adjunct to right heart catheterization in patients with Pulmonary Arterial Hypertension (WHO Group 1) to add information to improve clinical decision making. No agents are currently approved for this indication. Prior to conducting a Phase 3 registration study, GeNO LLC will first conduct this Phase 2, 10-patient pilot study to obtain preliminary safety and feasibility data from short term (15 minute) administration of inhaled nitric oxide via the GeNO Gas Cylinder NITROSYL System.  

GeNO's stand-alone gas cylinder stores premixed nitric oxide as nitrogen dioxide in either air or oxygen. The gas is allowed to flow through GeNO's proprietary cartridge containing ascorbic acid, which generates nitric oxide immediately prior to inhalation. A second cartridge is provided for redundancy

Leading researchers from four major medical centers will participate in the NITROSYL Phase 2 trial, including: Robert C. Bourge, M.D., Director, Division of Cardiovascular Disease at University of Alabama at Birmingham; Ioana Preston, M.D., Assistant Professor of Medicine at the Tufts University School of Medicine and the Co-Director for the Pulmonary Hypertension Center at Tufts Medical Center; Robert Schilz, D.O., Ph.D., Medical Director of Lung Transplant and Pulmonary Vascular Disease at UH Case Medical Center; and Fernando Torres, M.D., Associate Professor of Internal Medicine- Pulmonary and Critical Care at The University of Texas Southwestern Medical Center.

"As we move for
'/>"/>

SOURCE GeNO LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXINâ„¢ IN SEPTIC SHOCK
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 The UPMC Center for Health Security ... the Emerging Leaders in Biosecurity Initiative (ELBI). As part ... field of biosecurity, UPMC has selected 28 US and ... of backgrounds, including biological science, medicine, policy, the military, ... "With the vision and support of the Defense Threat ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biologics and Biosimilars ... , The Global Biologics and ... in-depth study on the current state of the ... provides a basic overview of the industry including ...
(Date:3/4/2015)... , March 4, 2015 AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... and breakthrough pain, today announced that it will ... after market close on Monday, March 9th, 2015. ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biologics and Biosimilars Industry Report 2015-2020 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
... long after the development of the first laser in 1960 ... light of a different color; more specifically, it produced light ... was dubbed second harmonic generation. The green laser ... this science, but producing such a beautiful emerald beam is ...
... DURHAM, N.C. -- Even with today,s invisibility cloaks, people ... of electrons can. The electrons perform this trick, ... move into a region of space that is normally ... is that as millions of electrons collectively move through ...
... of Technology have for the first time provided ... growing high-quality layers of epitaxial graphene on silicon ... vapor pressure of gas-phase silicon in the high-temperature ... basic principle for growing thin layers of graphene ...
Cached Biology Technology:Stanford engineers create nanoscale nonlinear light source 2Stanford engineers create nanoscale nonlinear light source 3Stanford engineers create nanoscale nonlinear light source 4Scientists observe how superconducting nanowires lose resistance-free state 2Scientists observe how superconducting nanowires lose resistance-free state 3Controlling silicon evaporation allows scientists to boost graphene quality 2Controlling silicon evaporation allows scientists to boost graphene quality 3
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... 26, 2015   Epic Sciences , a precision diagnostics ... that Murali Prahalad , Ph.D., president and CEO, is ... (PMWC) 2015: Silicon Valley, which is taking place at ... on January 26-28, 2015. Dr. ... as Biomarkers." Last year, Epic Sciences was a finalist in ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... type of coronavirus, the Middle East Respiratory Syndrome Coronavirus, MERS-CoV, ... died. It took several months before it was discovered that ... from Jordan, Qatar, Saudi Arabia, and the United Arab Emirates). ... imported cases coming from the Middle East. The virus has ...
... joint problems? Although researchers and clinicians have long known ... - periodontal disease and rheumatoid arthritis (RA) - the ... published today in PLOS Pathogens , University of ... group researcher Jan Potempa, PhD, DSc, and an international ...
... Over time, the esoteric and sometimes downright strange ... and others looking for perceived examples of waste in ... microbiologist Tom Brock,s National Science Foundation-supported treks to Yellowstone ... springs might easily have been singled out as yet ...
Cached Biology News:SARS virus treatments could hold the key for treatment of MERS-CoV outbreak 2Bacteria responsible for gum disease facilitates rheumatoid arthritis 2Decades on, bacterium's discovery feted as paragon of basic science 2Decades on, bacterium's discovery feted as paragon of basic science 3
... cDNA Labeling System - dCTP with ... For the generation and purification of ... packaged together for complete cDNA labeling ... be used for performing labeling reactions ...
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... with CyScribe GFX Purification Kit, 24 ... of Cy3- and Cy5-labeled cDNA.Optimized reagents ... labeling and purification.Flexible and optimized protocols ... reactions with either Cy3- or Cy5-labeled ...
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
Biology Products: